Author

Vanessa Barn

Australian National University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Adrià ClosaiD· 1 shared Alisee HugloiD· 1 shared Amee J. GeorgeiD· 1 shared Ashlee K. ClarkiD· 1 shared Denis Drygin· 1 shared Eduardo EyrasiD· 1 shared Eric P. KusnadiiD· 1 shared Gail Petuna RisbridgeriD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adrià ClosaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies.

Rita Ferreira, Katherine M. Hannan, Kostya I. Panov, Thejaani P. Udumanne, Amee J. George, Adrià Closa, Zaka Wing-Sze Yuen, Eduardo Eyras, Perlita Poh, Kylee H. Maclachlan, Mitchell Dwyer, Vanessa Barn, Jin-Shu He, Eric P. Kusnadi, Richard J. Rebello, , Nadine Hein

This study shows PMR-116, a second-generation RiBi inhibitor, effectively targets high-MYC cancers without causing DNA damage, suggesting RiBi as a viable cancer therapy.

bioRxiv · Apr 19, 2025 · PreprintCancer Biology